SIGA Secures Contract Valued at Up to $15 Million from Canadian Department of National Defence to Purchase TPOXX®
Key Highlights
- ➤SIGA secured a Canadian contract worth up to approximately $15 million through March 31, 2031
- ➤Approximately $9 million represents firm commitments over the contract’s first three years
- ➤Approximately $6 million remains subject to Canadian Department of National Defence options
- ➤Canada awarded SIGA its second TPOXX procurement contract through Public Services and Procurement Canada
Expert Statements
Diem Nguyen, Chief Executive Officer of SIGA Technologies
“Canada has been a consistent leader in smallpox preparedness, and this award reflects its sustained commitment to ensuring its military is ready to respond to a potential outbreak.”
Diem Nguyen, Chief Executive Officer of SIGA Technologies
“Canadian Armed Forces members are often among the first called upon in a public health emergency, and ready access to an approved smallpox antiviral helps ensure they can safely and effectively carry out that mission.”
Diem Nguyen, Chief Executive Officer of SIGA Technologies
“We are proud to continue supporting Canada and look forward to further strengthening our relationships with other governments around the world as we do our part to help protect populations from smallpox.”
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that Public Services and Procurement Canada (PSPC) has awarded SIGA a new contract for the procurement of oral TPOXX® (tecovirimat), an antiviral medication used to treat smallpox, on behalf of the Canadian Department of National Defence (CDND) through its Strategic Medical Countermeasures Program. The contract provides for the purchase of up to approximately $15 million by March 31, 2031, of which approximately $9 million represents firm commitments over the first three years of the contract and approximately $6 million is subject to option exercise by the CDND.
This contract is the second contract for TPOXX® awarded by PSPC on behalf of CDND. In April 2020, PSPC awarded a contract for the purchase of up to approximately $14 million of oral TPOXX®, and the final delivery under that contract was made in 2025.
Get started
Create a free account to read the full story.